Published by Global Banking & Finance Review®
Posted on January 17, 2025
2 min readLast updated: January 27, 2026
Add as preferred source on Google
Recordati and CVC Capital Partners deny any merger plans with Angelini Pharma, countering recent media speculation.
MILAN (Reuters) - Recordati and its top shareholder CVC-TELECOM-ITALIA-872b0395-cbf6-4eb0-8970-2791f7b16e49>CVC Capital Partners on Friday denied any plans to combine the Italian drugmaker with smaller rival Angelini Pharma.
"CVC-TELECOM-ITALIA-872b0395-cbf6-4eb0-8970-2791f7b16e49>CVC Capital Partners... is not contemplating a transaction with Angelini Pharma or its shareholders," CVC said in a joint statement with Recordati.
The private equity firm and the drugmaker said there were no contacts with Angelini, adding they did "not envisage any dialogue taking place in the future with either the management or the shareholders of Angelini Pharma."
The comments came after reports in the Italian press this week about a potential tie-up between the two drug firms.
On Friday, Italian daily Il Sole 24 Ore said that the family that owns Angelini Pharma could transfer its pharmaceutical business into a new company and then merge that with rival Recordati. The paper said both sovereign and pension funds had been sounded out about a potential co-investment in the venture.
In November, following an earlier report about the potential tie-up, Angelini Pharma declined to comment on its possible interest for Recordati, adding it "always looks at all market opportunities."
Recordati has a market capitalization of more than 11 billion euros.
(Reporting by Elvira Pollina and Elisa Anzolin, editing by Giulia Segreti and Valentina Za)
The article discusses Recordati and CVC Capital Partners denying any merger plans with Angelini Pharma.
No, both Recordati and CVC Capital Partners have denied any plans for a merger with Angelini Pharma.
The Italian press speculated about a potential merger between Recordati and Angelini Pharma.
Explore more articles in the Finance category
